GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Asset Turnover

Alto Neuroscience (Alto Neuroscience) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Alto Neuroscience's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Alto Neuroscience's Total Assets for the quarter that ended in Mar. 2024 was $148.28 Mil. Therefore, Alto Neuroscience's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Alto Neuroscience's annualized ROE % for the quarter that ended in Mar. 2024 was -88.39%. It is also linked to ROA % through Du Pont Formula. Alto Neuroscience's annualized ROA % for the quarter that ended in Mar. 2024 was -36.19%.


Alto Neuroscience Asset Turnover Historical Data

The historical data trend for Alto Neuroscience's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Asset Turnover Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Asset Turnover
0.01 - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial - - - - -

Competitive Comparison of Alto Neuroscience's Asset Turnover

For the Biotechnology subindustry, Alto Neuroscience's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Asset Turnover falls into.



Alto Neuroscience Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Alto Neuroscience's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (50.854+86.628)/ 2 )
=0/68.741
=0.00

Alto Neuroscience's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (86.628+209.922)/ 2 )
=0/148.275
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Alto Neuroscience  (NYSE:ANRO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Alto Neuroscience's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-53.668/60.716
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-53.668 / 0)*(0 / 148.275)*(148.275/ 60.716)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*2.4421
=ROA %*Equity Multiplier
=-36.19 %*2.4421
=-88.39 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Alto Neuroscience's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-53.668/148.275
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-53.668 / 0)*(0 / 148.275)
=Net Margin %*Asset Turnover
= %*0
=-36.19 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Alto Neuroscience Asset Turnover Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus